Effect of pulmonary tuberculosis on mortality in patients receiving HAART
- 27 March 2009
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 23 (6) , 707-715
- https://doi.org/10.1097/qad.0b013e328325d115
Abstract
Objective: To estimate the effect of ongoing treatment for pulmonary tuberculosis (PTB) at time of initiation of HAART on subsequent risk of death. Design: Evaluation of an open cohort of 7512 patients who initiated HAART between April 2004 and March 2007 in the Themba Lethu Clinic in Johannesburg, South Africa. Methods: Mortality hazard ratios were estimated using marginal structural Cox proportional hazards models to control for bias due to both confounding and loss to follow-up. Extensive sensitivity and secondary analyses were performed. Results: Although the crude hazard ratio for mortality in HAART-treated patients comparing those with and without treated PTB was 1.71 (95% confidence interval 1.31–2.23), the adjusted hazard ratio was 1.06 (95% confidence interval 0.75–1.49), indicating no difference in mortality risk. Similar effects were found when we considered different durations of time between initiation of PTB treatment and HAART, and sensitivity analysis confirmed main results. Secondary analysis suggested that individuals with PTB and other risk factors for death might be at particularly high risk of death during HAART treatment. Conclusion: The increase in death that we observed among individuals with PTB at the time of HAART initiation appears not to be due to the to the presence of PTB, but instead to confounding factors such as low CD4 cell count, low BMI, and WHO stage IV disease. These results further demonstrate that initiation of HAART soon after initiation of PTB treatment is not likely to put patients at higher risk of death.Keywords
This publication has 29 references indexed in Scilit:
- Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicinHIV Medicine, 2008
- Immune Reconstitution and “Unmasking” of Tuberculosis during Antiretroviral TherapyAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective studyAIDS, 2008
- Determining the Effect of Highly Active Antiretroviral Therapy on Changes in Human Immunodeficiency Virus Type 1 RNA Viral Load using a Marginal Structural Left-censored Mean ModelAmerican Journal of Epidemiology, 2007
- Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural UgandaAIDS, 2007
- Rapid Scale-up of Antiretroviral Therapy at Primary Care Sites in ZambiaJAMA, 2006
- Sensitivity Analysis and Potential Uses of a Novel Gamma Interferon Release Assay for Diagnosis of TuberculosisJournal of Clinical Microbiology, 2006
- Estimating causal effects from epidemiological dataJournal of Epidemiology and Community Health, 2006
- Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western KenyaAIDS, 2006
- Marginal Structural Models as a Tool for StandardizationEpidemiology, 2003